BMY Q1 2018 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q1 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.2B+5.4% YoY

Gross Profit

$3.6B69.4% margin

Operating Income

$1.4B26.8% margin

Net Income

$1.5B28.6% margin

EPS (Diluted)

$0.91

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$936M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$33.1B

Total Liabilities

$20.2B

Stockholders' Equity

$12.8B

Cash & Equivalents

$5.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.2B	$4.9B	+5.4%
Gross Profit	$3.6B	$3.7B	-2.9%
Operating Income	$1.4B	$1.6B	-13.7%
Net Income	$1.5B	$1.6B	-5.6%

Revenue Segments

Opdivo

$1.5B29%

Eliquis

$1.5B29%

Orencia

$593M11%

Sprycel

$438M8%

Other Legacy Brands

$405M8%

Yervoy

$249M5%

Baraclude

$225M4%

Reyataz

$124M2%

Sustiva Franchise

$84M2%

Empliciti

$55M1%

Hepatitis C Portfolio

$3M0%

Geographic Segments

UNITED STATES

$2.8B53%

Europe

$1.4B27%

Rest Of World

$873M17%

Other Region

$136M3%